Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03674411 · ClinicalTrials.gov registry record · Phase 2
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
A Phase 2 study of Acute Myeloid Leukemia and Mantle Cell Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03674411 is a Phase 2 study of Acute Myeloid Leukemia and Mantle Cell Lymphoma that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 22 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03674411, a Phase 2 study of Acute Myeloid Leukemia and Mantle Cell Lymphoma, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recovery. Patients will receive a uniform myeloablative conditioning and post-transplant immunoprophylaxis.
Conditions Studied
Interventions
- DRUG Tacrolimus (Tac)
- DRUG Fludarabine (FLU)
- DRUG Mycophenolate Mofetil (MMF)
- DRUG Cyclophosphamide (CY)
- DRUG Total Body Irradiation (TBI)
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03674411
The ClinicalTrials.gov registry entry for NCT03674411 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (81% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Tacrolimus (Tac) is the first listed.
NCT03674411 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03674411 about?
NCT03674411 is a clinical study titled "Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy". This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recovery. Patients will r...
What is the current status of trial NCT03674411?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2019-01-02. Estimated completion is 2026-12-01.
What conditions does trial NCT03674411 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Acute Lymphocytic Leukemia.
What interventions are being tested in trial NCT03674411?
The interventions under investigation include: Tacrolimus (Tac) (DRUG), Fludarabine (FLU) (DRUG), Mycophenolate Mofetil (MMF) (DRUG), Cyclophosphamide (CY) (DRUG), Total Body Irradiation (TBI) (DRUG).
Who is sponsoring clinical trial NCT03674411?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03674411 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.